Recruiting
Phase 2

Sibeprenlimab

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Code:

NCT06740526

Conditions

IgA Nephropathy

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

Sibeprenlimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-09. This information was provided to ClinicalTrials.gov by Otsuka Pharmaceutical Development & Commercialization, Inc. on 2025-04-06.